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Abstract
Background: Older age at organ transplantation is associated with increased risk of infection and malignancy but
reduced risk of cellular rejection. De novo donor-specific anti-HLA antibodies (dnDSA), are key biomarkers
associated with reduced long-term allograft survival, yet there is a lack of data focusing on age-associated changes.
Methods: Development of dnDSA was restrospectively analyzed in all subjects who received a kidney transplant at
the University Hospital Zurich between 01/2006 and 02/2015. Follow up continued until 03/2016. The incidence of
dnDSA in different age categories was compared with special focus on the extremes of age: children < 10 years
(n = 19) and adults ≥60 years of age (n = 110).
Results: Incidence of dnDSA gradually decreased with age, with older recipients having a significantly lower risk
(HR 0.21, p = 0.0224) compared to pediatric recipients. Cumulative incidence of dnDSA at 2, 5 and 10 years was 6.2,
9.1 and 36% in the older recipients versus 5.3, 29.5 and 47.1% in pediatric recipients. Median time to development
of dnDSA was similar (older 720 days, min 356, max 3646 days; children 1086 days, min 42, max 2474 days). Annual
incidence was highest within the first two years after transplantation in the older recipients and peaked in years
two to four in pediatric recipients. DnDSA were predominantly class II. More dnDSA were observed with
cyclosporine as compared to tacrolimus.
Conclusion: Older kidney transplant recipients have a lower risk of developing dnDSA than pediatric recipients,
pointing towards reduced humoral immune reactivity with increasing age. This observation raises the question of
adjustment in immunosuppression.
Keywords: De novo donor specific antibodies, Aging, Older kidney transplant recipients, Pediatric kidney transplant
recipients, Immunosenescence
Introduction
In recent years, interest in the changing immune reactiv-
ity over the life course has increased, as the number of
older transplant recipients is steadily rising [1, 2].
Consideration of changing immune reactivity with
increasing age, generally known as inflamm-aging and
immunosenescence [3–6], is essential in the unique
context of organ transplantation. While inflamm-aging
collectively refers to the increased level of stimulation of
the innate immune system, the concept of immunose-
nescence refers to alterations in the adaptive immune
system with decreased numbers of naïve T cells. The
reduced ability to mount immune responses against
novel antigens with increasing age is associated with
increased risks of infection and malignancy and reduced
vaccination responsiveness [3]. Particularly in the setting
of organ transplantation, where the risk of rejection
needs to be balanced with the risk of infections and
malignancies [7], this changing immune reactivity with
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age should be considered in order to optimize immuno-
suppressive drug dosing [8]. In the field of organ trans-
plantation, most studies comparing old with young
transplant recipients have focused on T-cell responses [9]
and have indeed described reduced frequency of acute
T-cell mediated rejections in older kidney transplant re-
cipients as compared to pediatric recipients [10, 11]. Few
studies have investigated antibody responses, i.e. develop-
ment of dnDSA against specific HLA-antigens despite in-
creasing recognition of the key role for antibody-mediated
rejection on long-term graft survival [12, 13]. In addition,
existing studies almost exclusively associate aging with old
age and studies on immune responses in pediatric recipi-
ents are scarce. This study focuses on the changing
immune reactivity of the humoral immune responses in
kidney transplant recipients, comparing the incidence of
dnDSA in different age groups with a special focus on the
those under 10 years and over 60 years of age.
Methods
Patient population: inclusion and exclusion criteria
In this longitudinal retrospective analysis all patients
receiving a first single kidney transplant at the University
Hospital of Zurich between January 2006 and February
2015 were eligible for inclusion. Follow up continued
until March 2016. In depth analysis of changing
immune-reactivity was performed for all children < 10
years of age and for adults ≥60 years of age.
In order to minimize bias from medication non-adher-
ence known to be up to 43% in adolescent transplant re-
cipients as compared to 22% in children and adults, we
defined the pediatric reference cohort as children younger
than 10 years of age [14–16]. As biological aging repre-
sents a spectrum, no clear clinical cut off for age has been
defined for older transplant recipients. Changes associated
with immunosenescence are described to start by 50 years
of age [9, 17, 18] and by general convention organ donors
older than 60 years of age are considered extended criteria
donors, due to differences in immunogenicity of older
donor organs [10, 19]. We therefore selected 60 years of
age to define the older transplant recipient cohort [9].
Patients were excluded if the following were present:
pre-existing DSA, missing donor typing information on
DQ locus and possible DSA in the Luminex single bead
assay (SAB) according to HLA associations, DSA MFI
levels below 1000 in the Luminex SAB and patients with
incomplete follow up data. The study was approved by the
local ethics committee of Zurich (protocol number:
KEK-ZH-Nr. 2017–00500).
Follow up of transplant patients, immunosuppression
regimens and Luminex assays
During the first year after transplantation, patients were
followed closely in the transplant clinic. Thereafter,
patients were seen at least yearly. Induction therapy with
basiliximab or thymoglobulin was used in patients at
high risk for rejection. Maintenance immunosuppression
consisted mostly of a calcineurin inhibitor (cyclosporine
A or tacrolimus) and an anti-proliferative drug (generally
mycophenolic acid). Steroids were withdrawn 6months
after transplantation in the majority of patients. Target
trough levels at 6, 12 and 24 months were 100-160 ng/
ml, 80-120 ng/ml, 50-80 ng/ml and 7-10 ng/ml, 6-8 ng/
ml, 4-6 ng/ml, for cyclosporine and tacrolimus respect-
ively. When the post-transplant course was uncompli-
cated, HLA-specific antibody testing was done yearly.
With graft dysfunction additional HLA-specific antibody
testing was performed. Testing was done using LABSc-
reen Mix Class I and II antibody screening kit
(OneLambda, Canoga Park, CA). If the Luminex mix
screening assay was positive, a specific Class I and/or
Class II LAB Screen single-antigen assay was added
(OneLambda, Canoga Park, CA). The data was analyzed
using the kit specific HLA Fusion software (One
Lambda). Antibodies to all loci (HLA-A, B- C, DR, DP
and DQ) were included. Donor and recipients were
typed for HLA-A, B, DR and from 2012 onwards for
DQ). Typing was done using PCR-SSP based molecular
typing method (Protrans, Mannheim, Germany) [20].
Calculated mean fluorescence intensity (MFI) values
were normalized against the internal negative control
and the negative serum control. If an allele specific
antibody against the donor was discovered in the single
antigen Luminex screening assay, it was declared as
DSA. A cutoff of 1000 MFI was chosen according to the
Swiss Organ Procurement System (SOAS). The DSA
with the highest MFI was defined as the peak DSA.
Statistical analysis
Occurrence of dnDSA after transplantation in the two
age groups was analyzed using Kaplan Meier curves.
The log rank test was used for curve comparison. Peak
MFI of dnDSA was compared between the two groups
with Mann Whitney U Test. The Chi square test was
used to compare immunosuppressive medication in pa-
tients with and without development of dnDSA. Graph
Pad Prism 5 Software were used for statistical analyses.
Results
Patient cohort
Of 482 patients who received a single first kidney trans-
plant between January 2006 and February 2015, 401
patients met inclusion criteria. A detailed patient flow
chart is shown in Fig. 1. Patient distribution into
different age groups and baseline characteristics are re-
ported in Table 1. Median follow-up time did not signifi-
cantly differ between the different age groups (p = 0.54;
Table 1). The average number of mismatches per locus
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for the extremes of age groups are indicated in
Additional file 1: Table S1.
Gradual decrease of de novo DSA with increasing
recipient age
A significantly lower risk for development of dnDSA
was observed in transplant recipients in the age groups
50–59 years (HR 0.18; p = 0.014) and ≥ 60 years of age
(HR 0.21, p = 0.22) as compared to children (< 10 years
of age). Risk of developing DnDSA was not significantly
higher among adolescents compared with younger pa-
tients (HR 0.42, p = 0.20). Overall, a tendency towards
decreasing risk for development of dnDSA with increas-
ing age was observed, Fig. 2a. Comparison between the
two extremes of age is highlighted in Fig. 2b. Cumulative
prevalence of dnDSA for the different age groups is
shown in Table 2. Further indepth analysis focused on
the age extremes comparing older transplant recipients
≥60 years (i.e. older recipient cohort) and children < 10
years (i.e. pediatric recipient cohort). Cumulative inci-
dence of dnDSA at 2, 5 and 10 years for the older cohort
was 6.2, 9.1 and 36% as compared to 5.3, 29.5 and 47.1%
in the pediatric cohort. Annual incidence of dnDSA was
highest in the first two years after transplantation for the
older recipients, whereas annual incidence peaked be-
tween two and four years after transplantation in the
pediatric recipients (Fig. 3a). Yet, median time to devel-
opment of DSA was similar in the older recipient cohort
(720 days; min 356, max 3646 days) and in the pediatric
recipient cohort (1086 days; min 42, max 2474 days).
Mean age at occurrence of dnDSA was 71 years in the
older recipient cohort and 8 years in the pediatric recipi-
ent cohort. Peak DSA was mostly a class II HLA
antibody in both recipient cohorts (5 out of 6 in
pediatric recipients; 9 out of 12 in older recipients),
Additional file 1: Table S2. MFI of the peak dnDSA was
not statistically different between the pediatric recipients
(mean peak MFI 6408) and the older recipients (mean
peak MFI 7023, Additional file 1: Figure S1). Of note,
similar percentages of patients displayed dnDSA with
MFI > 5000 and with MFI > 10′000 respectively
(pediatric recipients: 3/6 with dnDSA MFI > 5000 and 2
out of these with MFI > 10′000, older recipients: 6/12
with dnDSA MFI > 5000 and 4 out of these with MFI >
10′000).
Immunosuppression
DnDSA developed significantly more often among older
recipients receiving cyclosporine- compared with
tacrolimus-based regimens (Fig. 3b and Additional file 1:
Table S3). A similar trend was observed in pediatric
recipients, which did not reach statistical significance.
Fig. 1 Study Flow Chart
Table 1 Study population
Children < 10y Adolescent 10-19y 20-29y 30-49y 50-59y Old ≥ 60y
Total number 19 25 26 117 104 110
Mean age at transplantation 6 ± 3 15 ± 3 25 ± 3 43 ± 5 56 ± 3 65 ± 4
Male gender, n (%) 10 (53%) 17 (68%) 16 (62%) 81 (69%) 66 (63%) 83 (75%)
Deceased transplant n (%) 11 (58%) 16 (64%) 3 (12%) 59 (50%) 60 (58%) 76 (69%)
Median follow up time, days
(min; max)
1971 (356; 3420) 1405 (289; 3427) 1788 (343; 3444) 1790 (157; 3645) 1841 (154; 3624) 1602 (141; 3612)
HLA mismatches were calculated for loci HLA A, B (class I) and DR, DQ (class II)
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Fig. 2 Cumulative incidence of dnDSA after kidney transplantation as determined by Kaplan Meier survival curves. a Comparison between all age
groups, b) Comparison between the older recipient cohort and the pediatric recipient cohort using Log rank test. Subjects at risk for developing
dnDSA in each time period are shown
Table 2 Risk of development of dnDSA in different age groups
Children < 10y Adolescent 10-19y 20-29y 30-49y 50-59y Old ≥ 60y
Cumulative prevalence dnDSA 32% (6/19) 12% (3/25) 19% (5/26) 13% (15/117) 11% (11/104) 11% (12/110)
Hazard ratio, p – HR 0.42 p = 0.205 HR 0.52 p = 0.312 HR 0.35 p = 0.088 HR 0.18 p = 0.014 HR 0.21 p = 0.022
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Discussion
Due to demographic changes, increasing numbers of pa-
tients aged over 60 years are being transplanted [1, 2].
Hence, investigation of changing immune reactivity over
the life course is increasing. In general, older recipient
age is an independent risk factor for post-transplant
mortality in all solid organ transplantations [9, 21], with
the highest risk being infection-associated death
followed by cardiovascular death and malignancies [22].
In contrast, the risk of acute cellular rejection is lower in
older transplants recipient compared with pediatric
recipients [23, 24]. These observations reflect changes in
the adaptive immune system summarized by the terms
‘immunosenescence’ and ‘inflamm-aging’. The reduced
risk of acute cellular rejections is consistent with thymic
involution and the limited T-cell receptor repertoire
observed with aging [6, 9, 21]. Additionally, humoral
immune responses in older patients have also been
shown to be altered, with increased memory responses
and a skewed B cell repertoire [11, 25, 26] which is more
specialized but less plastic to mount humoral immune
responses. Together with the reduced frequency of naïve
T cells these changes are associated with increased risk
of infections [11, 26]. By contrast, the heightened
A
B
Fig. 3 a Cumulative percentage of de novo DSA positivity in the cohort of recipients developing a donor specific humoral immune response:
n = 12 in the older cohort and n = 6 in the pediatric cohort. b Comparison of immunosuppressive medication (Cyclosporine = Cyc, Tacrolimus = Tac)
at time point of detection of de novo DSA between recipients with and without de novo donor specific humoral immune response in both cohorts,
i.e. older and pediatric patients. Comparison using Chi-square test
Moos et al. Immunity & Ageing            (2019) 16:9 Page 5 of 8
subclinical inflammation associated with inflamm-aging
and increased reactivity of the innate immune system
potentially contributes to increased cardiovascular risk
among older transplant recipients. Together, these as-
pects highlight the complex nature of immunological
changes associated with aging.
Given the major role of antibody-mediated responses
in determining long-term graft survival [12, 13], we
analyzed changes in humoral immune reactivity with
increasing age by investigating the incidence of dnDSA
in older kidney transplant recipients compared with
pediatric kidney transplant recipients. Our results
indicate that the risk of developing dnDSA is 4.8 to 5.6
times lower in older recipients as compared to pediatric
recipients (older aged ≥60 years HR 0.21; p = 0.0224).
Interestingly, we observed that the changing reactiv-
ity of the immune system may begin around age 50
years (HR 0.18, p = 0.014). Of note, the annual inci-
dence of dnDSA was highest during the first two
years post-transplantation in the older recipients,
while the annual incidence of dnDSA peaked be-
tween years two and four after transplantation in
pediatric recipients These early post-transplant years
are a time when immunosuppressive drug doses are
generally reduced. Consistent with the literature, the
majority of dnDSA were directed against HLA class
II, more specifically against HLA DQ locus [27, 28]
and dnDSA occurred significantly more frequently
with cyclosporine- rather than tacrolimus-based im-
munosuppression [22].
To our knowledge, this is the first study directly
comparing the incidence of dnDSA in older vs. pediatric
kidney transplant recipients. Few small studies have in-
vestigated the development of dnDSA in older patients
from the European senior program, reporting variable
cumulative prevalences for dnDSA between 20 and 30%
at 5 to 10 years post transplantation [22, 29], numbers
that are higher than those observed in our cohort. Yet,
development of dnDSA after kidney transplantation is
highly variable with reports ranging from cumulative
prevalences from 13 to 30% in non-sensitized adult
kidney transplant recipients [30, 31]. This variability
could reflect differences in antibody MFI cut offs,
frequency of testing and baseline immunosuppression.
With respect to the young cohort, our data are consist-
ent with results from other centers reporting a cumula-
tive prevalence between 20 and 36% at 5 to 10 years
after transplantation [27, 32, 33].
A major strength of our study is the direct comparison
between the different age groups of transplant recipients
treated and followed up at the same hospital and tested
for development of dnDSA in the same laboratory. To
our knowledge this is the first study to directly compare
development of dnDSA across patient age groups
simultaneously and is therefore novel. We specifically
set the age limit for definition of the pediatric recipi-
ent cohort at age younger than 10 to minimize the
confounder of non-adherence, which is a relevant
problem in adolescent recipients [34–36]. All but one
pediatric recipient developed dnDSA at age ≤ 10 years
of age (Additional file 1: Table S4). Hence, the differ-
ences in incidence and prevalence of dnDSA are most
likely due to age-associated changes in immune re-
activity and do not reflect differences in medication
adherence. Assessment of medication adherence was
however not possible in this retrospective study. The
study does have several limitations. Subject numbers
included in the extremes of age groups were different.
Given the retrospective nature of the study, data re-
garding C1q binding of the dnDSA was not available.
We did not investigate the effect of donor-recipient
age ratio, which is another limitation given the known
effect of organ age on immune reactivity [10, 19].
Additionally, at our center, we do not perform proto-
col biopsies, making a statement with respect to
histological changes related to development of dnDSA
impossible. Similarly, due to small patient numbers,
data on graft survival would not be meaningful and
in older adults is also highly impacted by comorbidi-
ties and not only rejection episodes [37]. Also,
chronological age might not be congruent with bio-
logical age, considering the multiple modifying extrin-
sic factors such as nutrition, exercise and previous
exposure to microorganisms [5] which adds to the
complexity of changing pharmacodynamics and
pharmacokinetics of immunosuppressive drugs with
age [38]. Pharmacokinetic studies were not possible in
this retrospective analysis.
In conclusion, this study adds to current knowledge
having investigated humoral immune responses after
kidney transplantation over the whole age spectrum. A
gradual decrease in incidence of dnDSA, with age was
observed, underscored by a significantly lower risk of
dnDSA in the older recipient cohort as compared to the
pediatric recipient cohort. Our observations may have
practical implications with respect to immunosuppres-
sive medication dosing and suggest that medication
levels should be tailored to the individual needs reflect-
ing the adaptive changes of immune reactivity associated
with aging. Further prospective studies, including
larger patient numbers and recipients of different
solid organ transplants, with monitoring of medica-
tion adherence, including pharmacodynamic and phar-
macokinetic studies as well as biomarkers associated
with biological aging [3, 4, 39] are needed to confirm
our data and to introduce a practical guidance on
immunosuppressive medication dosing in accordance
to transplant recipient age.
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